Phase 2, Single-Arm, Open-Label Extension Study to Investigate Safety with Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study 1311.5

Assess the safety and tolerability of risankizumab in PsA subjects who have completed all doses of study drug and the Week 24 visit in Study 1311.5.